EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma

Hongwei Xu iD, Yani Liu, Haili Zhang, Haojun Wu, Bo Li, Kefei Chen, Yonggang Wei iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.71867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Hongwei Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Province Science and Technology Support Program, Sichuan Provincial Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter arterial chemoembolization (TACE) is widely used for intermediate‐advanced hepatocellular carcinoma (HCC). The efficacy and safety of TACE combined with systemic treatments as conversion therapy for HCC remain to be explored.

Methods

Patients with intermediate‐advanced HCC were divided as following groups based on therapy: (1) TACE; (2) TACE combined with tyrosine kinase inhibitors (TACE+TKI); (3) TACE+TKI and immune checkpoint inhibitors (TACE+TKI+ICI); and (4) TACE combined with Bevacizumab and ICI. The progression‐free survival (PFS), overall survival (OS), treatment responses, and adverse events (AEs) were evaluated.

Results

Of the enrolled 518 patients, the overall objective response rate (ORR) was 21.0% and disease control rate (DCR) was 63.7%, while the TACE+TKI+ICI group showed highest ORR (28.9%) and DCR (72.8%). 147 (28.4%) patients experienced AEs during treatments. The TACE+TKI+ICI group significantly improved survival compared to TACE (mPFS: 20.7 vs. 10.9 months, p < 0.001; mOS: 44.0 vs. 13.3 months, p < 0.001) or TACE+TKI (mPFS: 20.7 vs. 15.6 months, p = 0.011; mOS: 44.0 vs. 25.0 months, p < 0.001). Of the 117 (22.6%) patients who underwent conversion liver resection, both mPFS (p = 0.016) and mOS (p < 0.001) were significantly better than those without subsequent resection.

Discussion

This study demonstrated that TACE+TKI+ICI had a better ORR, manageable AEs, and superior PFS and OS compared to other TACE‐based conversion therapies. Undergoing subsequent liver resection significantly enhanced long‐term survival compared to non‐resection counterparts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularChemoembolization, TherapeuticAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedTreatment OutcomeCombined Modality TherapyProtein Kinase InhibitorsAdultImmune Checkpoint InhibitorsRetrospective Studies

Stichwörter der Autor:innen

TACEconversion therapyhepatocellular carcinomasurvival

Substanzen

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Department of General Surgery, West China Second Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Hongwei Xu, Yonggang Wei

Förderung

  • Sichuan Province Science and Technology Support Program
  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Xu, H., Liu, Y., Zhang, H., Wu, H., Li, B., Chen, K., & Wei, Y. (2026). Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71867

Vancouver

Xu H, Liu Y, Zhang H, Wu H, Li B, Chen K, et al. Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.71867

BibTeX
@article{Xu2026,
  author = {Xu, Hongwei and Liu, Yani and Zhang, Haili and Wu, Haojun and Li, Bo and Chen, Kefei and Wei, Yonggang},
  title = {Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71867}
}
Kostenlos starten →